• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Brainstorm’s NurOwn stem cell treatment for ALS readies for phase III

December 19, 2016 By Sarah Faulkner

Brainstorm readies phase III trial for NurOwn stem cell treatment for ALSBrainstorm Cell Therapeutics (NSDQ:BCLI) said today that it’s preparing for a phase III trial of its NurOwn stem cell treatment, after meeting with the FDA about a biologic license application. The company is developing adult stem cell therapies derived from autologous bone marrow cells to treat neurodegenerative diseases, such as ALS.

Hackensack, N.J.-based Brainstorm is planning a randomized, double-blind, multi-dose phase III trial at multiple sites across the U.S. and in Israel. The trial is slated to enroll patients in the 2nd quarter of next year.

“We are very pleased with the outcome of the End-of-Phase II meeting with the FDA, and we look forward to initiating our Phase III clinical trial for NurOwn in ALS,” president & CEO Chaim Lebovits said in prepared remarks. “Together with our clinical investigators in the U.S. and Israel, we have worked diligently with the FDA to advance NurOwn through to late-stage development.  Building off NurOwn’s safety and clinical efficacy observed to date, we are developing a phase III program that, if successful, will position us to bring to the market an innovative, disease modifying treatment for patients suffering from ALS.”

The company also said it plans to submit a hospital exemption application in Israel, in the hopes of partnering with a medical center and treating patients with NurOwn for a fee.  

“Our planned application for Hospital Exemption is our first step toward providing ALS patients with access to NurOwn,” said Mr. Lebovits. “Our decision to proceed with this application is based on a strong interest voiced by ALS patients via a questionnaire. We foresee possible treatments under this pathway as early as the second half of 2017.”

Filed Under: Clinical Trials, Featured, Food & Drug Administration (FDA), Neurological, Stem Cells Tagged With: Brainstorm Cell Therapeutics

IN CASE YOU MISSED IT

  • Medtronic Diabetes names CFO with consumer experience ahead of separation
  • Diabeloop launches insulin delivery algorithm in Germany
  • GlucoModicum has positive data for needle-free CGM
  • Lifecare takes next steps in CGM implant development
  • Ypsomed brings autoinjector for dual GCG/GLP-1 delivery to China

Reader Interactions

Comments

  1. Jody Brown says

    March 3, 2017 at 2:49 pm

    I have a sister that has just been diagnosed with als. She is in the early stages of als and we would like to find out how she can enroll in the phase 111 clinical study.

  2. jan berkhey says

    May 21, 2017 at 2:36 am

    my illnes is distal segmental spinal muscle atrophy, also a motorneuron desease, i would participate in the phase 3 study

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS